In this study, we analysed data from a large database to determine time-in-range, which is defined as ‘time spent with BCVA better than 20/40’, in patients receiving intravitreal anti-VEGF injections for age-related macular degeneration in a clinical setting. The gene discussed is VEGFA; the disease is age-related macular degeneration.